Compare DexCom, Inc. (DXCM) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Firy Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Firy Inc. trades at $12.07 (market cap $199.80M). The key difference: DexCom, Inc. is far larger — about 159.5× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Firy Inc. for 13 Days on average.
| DXCM | FIRY | |
|---|---|---|
Market Cap | $31.86B | $199.80M |
Volume | 3,607,070 | 92,993 |
Sector | Health | Technology |
52-Week High | $92.34 | $13.10 |
52-Week Low | $54.84 | $2.28 |
Typical Hold Time | 62 Days | 13 Days |
Enterprise Value | $31.32B | $168.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
FIRY trades at $12.02, up 1.43% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0M but missed EPS expectations with a net loss. Recent developments include a $719M legal victory and board appointment of Marc Lasry, though cash flow remains negative with -$86.41M in 2025.
Outlook is mixed: the legal win and restructuring offer potential upside, but persistent losses and cash burn pose significant risks. Analyst consensus is cautious with 60% hold ratings. The stock's valuation at P/S 1.6x appears reasonable, but profitability challenges and negative margins require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
